Navigation Links
NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis
Date:12/17/2008

SOPHIA ANTIPOLIS, France, December 17 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced positive results of a pre-specified pooled analysis of 2,734 patients with osteoarthritis (OA) from the 301, 302 and 303 pivotal phase 3 studies for naproxcinod. Both doses of naproxcinod showed a significant reduction in systolic and diastolic blood pressure (SBP and DBP) compared to naproxen 500 mg bid over the whole 13 week period (p<0.001 for naproxcinod 750 mg bid and p<0.05 for naproxcinod 375 mg bid). Naproxcinod is the first compound in a novel class of anti-inflammatory agents known as Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs).

A significantly lower proportion of patients on naproxcinod experienced an increase in SBP of 5 mmHg or more, compared to naproxen

Over the whole 13 week period the proportion of patients whose SBP increased by 5 mmHg or more was higher for naproxen 500 mg bid, as compared to naproxcinod 750 mg bid (p<0.001), naproxcinod 375 mg bid (p=0.013) and placebo (p<0.001).

Both naproxcinod doses showed a similar blood pressure profile to placebo, in contrast to naproxen which raised SBP (p<0.001)

There is a clear unmet medical need for a novel anti-inflammatory agent with no detrimental impact on blood pressure. COX-2 inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs), such as naproxen, are widely used for the symptomatic treatment of OA but can lead to the onset of new episodes of high blood pressure or worsening of pre-existing hypertension. Both doses of naproxcinod (375 and 750 mg bid) were similar to placebo, as indicated by one-sided 95% confidence intervals (CIs). In contrast, naproxen 500 mg bid raised SBP compared to placebo (p<0.001).

Garret FitzGerald, MD, Professor of Medicine and Pharmacology at the University of Pennsylvania School of Medicine, commented:
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

1379

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
2. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
3. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
4. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
5. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
6. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
7. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
10. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
11. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... and TORONTO ... Corporation ( www.generex.com ) (OTCQB: GNBT) today ... implement a buccal cannabis co-development arrangement with ... been formalized. Generex and CannScience ... Technology Licensing Agreement.  Pursuant to the Agreement, ...
(Date:9/2/2015)... , Sept. 2, 2015  MGC Diagnostics Corporation ... a conference call to discuss its financial results for ... 2015. The call will be at 4:30 p.m. ET ... financial results for the third quarter of fiscal 2015 ... Participants can dial (877) 317-6789 or ...
(Date:9/2/2015)... EVANSTON, Ill. , Sept. 2, 2015 ... and a frenzy of health care M&A activity – ... place moderate-to-severe access restrictions on pharmaceutical sales reps. This ... who limit access has crossed the halfway point, according ... global sales and marketing firm ZS . ...
Breaking Medicine Technology:Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3MGC Diagnostics Corporation to Report Third Quarter Fiscal 2015 Financial Results on Thursday, September 10, 2015 2Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5
... Sweden, Sept. 18 Forest,Laboratories (NYSE: FRX ... produced a significant bronchodilatory response in 17 patients,with ... trial presented today at the,European Respiratory Society (ERS) ... ) Results of the study showed ...
... Major study of more than 2,100 patients with hip fracture shows,significant 35% reduction ... The New England Journal of Medicine show, significant 28% reduction in ... ... receive osteoporosis treatments following hip fracture despite ...
Cached Medicine Technology:Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 2Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 3Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 4Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 5First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 2First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 3First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 4First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 5First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 6First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 7First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 8
(Date:9/2/2015)... ... ... On September 9, 2015, over 27,000 people from all over the world ... date for the state of Utah. , “We are thrilled with the overwhelming response ... doTERRA CEO. “One of the most exciting elements of our convention is the opportunity ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Brain Aneurysm Awareness Month , which was established by the Foundation in ... awareness and education, and helping fund more research remains our top priority,” commented ...
(Date:9/2/2015)... ... ... Mobile working is increasingly more important, as business professionals are looking to be ... being launched, and mobile device usage as a whole is something people around the ... lives. What's more people are expecting mobile versions of their favorite software. , While ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is National Prostate ... that affects more than 233,000 men each year in the United States. , Prostate ... common non-skin cancer in America, affecting 1 in 7 men. One new case occurs ...
(Date:9/1/2015)... Los Angeles, CA (PRWEB) , ... September 01, 2015 , ... ... the American Medical Association, individuals with type 2 diabetes that participated in a three ... of diabetes three years down the line if they elected weight loss surgery at ...
Breaking Medicine News(10 mins):Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2
... cells continue to flow to newborn in minutes after birth, ... women may want to consider asking their doctors to hold ... after the baby is born, a new study suggests. , ... the blood flow from mom to baby. While not necessarily ...
... experts say , WEDNESDAY, May 26 (HealthDay News) -- Malignant ... tens of thousands of genetic mutations which, together, contribute to ... lung tumor from a heavy smoker revealed 50,000 mutations, according ... Nature . , "People in the field have always known ...
... Complete Genomics Inc., a third-generation human genome sequencing company, ... of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), ... sequence and compare a patient,s primary lung tumor and ... to compare the patient,s genome before and after it ...
... treatment of anaplastic thyroid carcinoma has dramatically increased survival in ... say physicians at Mayo Clinic. Their findings will be presented ... Clinical Oncology , to be held June 4-8 in Chicago. ... to aggressively treat metastasis even when this rare cancer seems ...
... ... first Community of Respect™ Medical Center in the Anti-Defamation League’s (ADL’s) Southwest Region. ... ... the first Community of Respect™ Medical Center in the Anti-Defamation League’s (ADL’s) Southwest ...
... ... up to $100,000 per-violation penalties , ... Alexandria, VA (Vocus) May 26, 2010 -- More than ten major ... Network (CEN) offered by the National Association of Chain Drug Stores (NACDS) and RollStream. ...
Cached Medicine News:Health News:Waiting to Clamp the Umbilical Cord May Be Better for Babies 2Health News:Waiting to Clamp the Umbilical Cord May Be Better for Babies 3Health News:Single Lung Tumor Contains 50,000 Mutations 2Health News:Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature 2Health News:New treatment approach to rare cancer results in prolonged survival 2Health News:Houston Northwest Medical Center Becomes First Hospital in the Southwest Region Designated a Community of Respect&#8482; Partner 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 3
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: